6cps Citations

Disulfide bridge formation influences ligand recognition by the ATAD2 bromodomain.

Proteins 87 157-167 (2019)
Cited: 9 times
EuropePMC logo PMID: 30520161

Abstract

The ATPase family, AAA domain-containing protein 2 (ATAD2) has a C-terminal bromodomain, which functions as a chromatin reader domain recognizing acetylated lysine on the histone tails within the nucleosome. ATAD2 is overexpressed in many cancers and its expression is correlated with poor patient outcomes, making it an attractive therapeutic target and potential biomarker. We solved the crystal structure of the ATAD2 bromodomain and found that it contains a disulfide bridge near the base of the acetyllysine binding pocket (Cys1057-Cys1079). Site-directed mutagenesis revealed that removal of a free C-terminal cysteine (C1101) residue greatly improved the solubility of the ATAD2 bromodomain in vitro. Isothermal titration calorimetry experiments in combination with the Ellman's assay demonstrated that formation of an intramolecular disulfide bridge negatively impacts the ligand binding affinities and alters the thermodynamic parameters of the ATAD2 bromodomain interaction with a histone H4K5ac peptide as well as a small molecule bromodomain ligand. Molecular dynamics simulations indicate that the formation of the disulfide bridge in the ATAD2 bromodomain does not alter the structure of the folded state or flexibility of the acetyllysine binding pocket. However, consideration of this unique structural feature should be taken into account when examining ligand-binding affinity, or in the design of new bromodomain inhibitor compounds that interact with this acetyllysine reader module.

Reviews - 6cps mentioned but not cited (1)

  1. AAA ATPases as therapeutic targets: Structure, functions, and small-molecule inhibitors. Zhang G, Li S, Cheng KW, Chou TF. Eur J Med Chem 219 113446 (2021)

Articles - 6cps mentioned but not cited (1)



Reviews citing this publication (3)

  1. Functional Roles of Bromodomain Proteins in Cancer. Boyson SP, Gao C, Quinn K, Boyd J, Paculova H, Frietze S, Glass KC. Cancers (Basel) 13 3606 (2021)
  2. ATPase family AAA domain-containing protein 2 (ATAD2): From an epigenetic modulator to cancer therapeutic target. Fu J, Zhang J, Chen X, Liu Z, Yang X, He Z, Hao Y, Liu B, Yao D. Theranostics 13 787-809 (2023)
  3. Epigenetic-Mediated Regulation of Gene Expression for Biological Control and Cancer: Cell and Tissue Structure, Function, and Phenotype. Fritz AJ, El Dika M, Toor RH, Rodriguez PD, Foley SJ, Ullah R, Nie D, Banerjee B, Lohese D, Tracy KM, Glass KC, Frietze S, Ghule PN, Heath JL, Imbalzano AN, van Wijnen A, Gordon J, Lian JB, Stein JL, Stein GS. Results Probl Cell Differ 70 339-373 (2022)

Articles citing this publication (4)